WG
DGX icon

Winchester Group’s Quest Diagnostics DGX Stock Holding History

Winchester Group’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$2.61M Sell
42,215
-142
-0.3% -$8.5K 0.57% 54
2013
Q2 		$2.57M Buy
+42,357
New +$2.52M 0.55% 50

Other funds holding DGX

AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Winchester Group's DGX Position: Q3 2013 in Review

Winchester Group reduced its Quest Diagnostics (DGX) stake by 0.34% in Q3 2013, selling an estimated $8.5K and leaving 42,215 shares worth $2.61M. The position accounts for 0.57% of the portfolio, ranked #54.

Winchester Group first reported a position in DGX in Q2 2013 and has held it in 2 quarters since. 425 funds tracked by Wall St. Rank hold DGX as of Q3 2013.

  • Winchester Group held 42,215 shares of Quest Diagnostics worth $2.61M as of Q3 2013.
  • Winchester Group sold 142 Quest Diagnostics shares in Q3 2013, an estimated $8.5K.
  • Quest Diagnostics made up 0.57% of Winchester Group's portfolio in Q3 2013, its #54 holding.
  • Winchester Group first reported a position in Quest Diagnostics in Q2 2013 and has held it in 2 quarters since.
  • 425 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2013.

Based on Winchester Group's 13F filing for Q3 2013, filed 16 Oct 2013.